ADR Biomedical Holdings (TSE:3750) Total Current Liabilities: 円226.72 Mil (As of Mar. 2026)


TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円808.00
GF Value 円40.38
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Total Current Liabilities?

ADR Biomedical Holdings TSE:3750 +0.37% 30 Total Current Liabilities is 円226.72 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.38 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. ADR Biomedical Holdings's total current liabilities for the quarter that ended in Mar. 2026 was 円226.72

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

ADR Biomedical Holdings Total Current Liabilities Related Terms

ADR Biomedical Holdings Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Total Current Liabilities Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 995.49 1,173.62 536.18 491.75 226.72

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 536.18 351.73 491.75 197.00 226.72
TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

ADR Biomedical Holdings's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=166.768+0
+Other Current Liabilities+Current Deferred Liabilities
=59.953+0
=226.72

ADR Biomedical Holdings's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=166.768+0
+Other Current Liabilities+Current Deferred Liabilities
=59.953+0
=226.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of 円226.72 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Total Current Liabilities of 円226.72 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Total Current Liabilities too high?
ADR Biomedical Holdings' current Total Current Liabilities is 円226.72 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Total Current Liabilities compare to VRTX and REGN?
ADR Biomedical Holdings' Total Current Liabilities of 円226.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Total Current Liabilities is 円226.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.38, compared to a current price of 円808.00 — trading 1901% above its estimated fair value. The current Total Current Liabilities is 円226.72 Mil. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Total Current Liabilities is 円226.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円808.00 is trading 1901% above its estimated GF Value™ of 円40.38. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Total Current Liabilities: 円226.72 Mil
  • GF Value™: 円40.38 vs. price of 円808.00 (1901% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円808.00
Price
円40.38
GF Value